Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Our lead product candidate under active development is rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3. Rucaparib is in advanced clinical development for the treatment of ovarian cancer and we are initiating clinical development for the treatment of metastatic castration-resistant prostate cancer patients. We maintain global rights to rucaparib.
We collaborate with leading developers of companion diagnostics in support of our drug development efforts. Through these collaborations, we have flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel our own regulatory and commercialization paths.